GEN Exclusives

More »

GEN News Highlights

More »
Jun 18, 2007

Ablynx Reaches Milestone with Proctor & Gamble

  • Ablynx reached a second milestone in its collaboration with Procter & Gamble Pharmaceuticals (P&GP). The company discovered novel Nanobodies® against a second target for possible new treatments in the musculoskeletal area. The first milestone was achieved in December 2006.

    As part of this on-going collaboration Ablynx is responsible for discovering nanobodies that meet an agreed product profile. P&GP is responsible for the pre-clinical and clinical development of Nanobodies®, as well as the commercialization of any resulting drug products.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »